Welcome to our dedicated page for Kyverna Therapeutics SEC filings (Ticker: KYTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kyverna Therapeutics filings document a late-stage clinical biopharmaceutical company developing cell therapies for autoimmune diseases. Its Form 8-K disclosures frequently cover Regulation FD updates for miv-cel clinical data, business and financial results, and material corporate events involving leadership, board composition, and commercial organization changes.
The company's proxy and governance filings describe director elections, board committees, executive compensation, stockholder voting matters, and equity incentive arrangements, including inducement awards. SEC records also identify Kyverna's Nasdaq-listed common stock and provide formal disclosure around its CAR T development strategy, clinical programs in neuroimmunology, capital planning, risk factors, and public-company governance.
Kyverna Therapeutics calls a fully virtual 2026 annual meeting on May 27, 2026, asking stockholders to elect two Class II directors, Ian Clark and Christi Shaw, and ratify BDO USA as auditor for 2026.
The proxy highlights 2025 as a transformative year, with registrational data in stiff person syndrome supporting a planned BLA filing in the first half of 2026, strong Phase 2 results in generalized myasthenia gravis backing an FDA‑aligned Phase 3 trial, early signals in multiple sclerosis and rheumatoid arthritis, and a strengthened balance sheet extending cash runway into 2028.
KYTX filed a Form 144 reporting the proposed sale of 17,578 shares of Common Stock via a stock option exercise to be effected on 04/07/2026 for cash. The filing also discloses a prior sale of 16,634 shares on 03/31/2026 for $140,404.27.
Kyverna Therapeutics has registered up to $100,000,000 of its common stock for sale in an at‑the‑market offering through Jefferies LLC acting as sales agent. Sales may occur from time to time under a Sales Agreement dated March 27, 2025, with Jefferies receiving a 3.0% commission on gross proceeds.
The prospectus shows 60,389,893 shares outstanding as of December 31, 2025 and gives an illustrative example of selling 12,594,458 shares at an assumed price of $7.94 per share resulting in up to 72,984,351 shares outstanding. Net proceeds are intended for general corporate purposes, including R&D, capital expenditures, working capital and general administrative expenses.
Kyverna Therapeutics, Inc. has registered a shelf offering to sell up to $300,000,000 of securities from time to time and included a sales agreement prospectus for up to $100,000,000 of common stock to be sold under an Open Market Sale Agreement with Jefferies LLC.
The base prospectus covers a range of instruments including common stock, preferred stock, debt securities, warrants, rights, units and depositary shares, with specific terms to be provided in prospectus supplements. The company’s common stock trades on Nasdaq under the symbol KYTX; the last reported sale price cited here was $7.87 per share as of March 25, 2026.
Kyverna Therapeutics, Inc. presents an annual overview as a late-stage clinical biopharmaceutical company developing CD19-directed cell therapies for autoimmune diseases. Its lead autologous CAR T candidate, mivocabtagene autoleucel (miv-cel / KYV-101), targets B cells to reset the immune system and aims for durable, treatment-free remission.
The company has completed a registrational Phase 2 SPS trial (KYSA-8) with a highly significant improvement in walking ability, plans a BLA filing in the first half of 2026, and has RMAT and orphan designations in SPS and MG. In generalized myasthenia gravis, positive Phase 2 data support an ongoing Phase 3 KYSA-6 trial against standard of care.
Additional programs explore miv-cel in multiple sclerosis, rheumatoid arthritis, lupus nephritis and systemic sclerosis through company and investigator-initiated studies. A next-wave autologous product, KYV-102, uses a rapid whole-blood manufacturing process, and KYV-201 is an allogeneic CD19 CAR T developed with Intellia. Kyverna states that its cash, cash equivalents and marketable securities are expected to provide runway into 2028, funding the planned SPS BLA submission, SPS commercial launch preparation and the Phase 3 gMG trial.
Kyverna Therapeutics reported its fourth quarter and full year 2025 results while highlighting major progress for its lead autoimmune CAR T therapy, miv-cel. The company is preparing a Biologics License Application for stiff person syndrome in the first half of 2026 and aims to be launch-ready by year-end 2026.
Kyverna is also advancing an FDA-aligned Phase 3 trial in generalized myasthenia gravis and reported encouraging data from investigator-initiated studies in progressive multiple sclerosis and rheumatoid arthritis. The company strengthened its balance sheet through $147.5 million in financings and ended 2025 with $279 million in cash, expecting runway into 2028 despite a 2025 net loss of $161.3 million.
Kyverna Therapeutics, Inc. reported that its Chief Financial Officer, Marc Grasso, received new equity awards as part of his compensation. He was granted a stock option for 65,000 shares of common stock at an exercise price of $8.95 per share, expiring on March 13, 2036. He also received 10,000 shares of common stock in the form of a restricted stock unit award.
According to the vesting terms, one quarter of the restricted stock units will vest on March 13, 2027, with the remaining three quarters vesting in equal annual installments on each one-year anniversary thereafter, subject to his continued service. For the stock option, one quarter of the shares will vest on March 13, 2027, and the remaining shares will vest in equal monthly installments (1/48th each month) thereafter, also contingent on continued service to the company.
Kyverna Therapeutics’ Chief Executive Officer Biddle Warner Weston received new equity awards as part of his compensation. He was granted stock options for 350,000 shares of common stock at an exercise price of $8.95 per share, expiring on March 13, 2036. One quarter of these options vest on March 13, 2027, with the remaining shares vesting in equal monthly installments of 1/48 each month thereafter, contingent on his continuous service.
He also received a restricted stock unit award covering 58,000 shares of common stock. One quarter of this RSU grant vests on March 13, 2027, and an additional one quarter vests on each one-year anniversary after that date, also subject to continued service. Following these awards, his reported holdings include 58,000 shares of common stock and 350,000 options, reflecting compensation-related acquisitions rather than open-market purchases.